Literature DB >> 15573398

Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.

Gerald J Atkins1, Panagiota Kostakis, Katie J Welldon, Cristina Vincent, David M Findlay, Andrew C W Zannettino.   

Abstract

While it has been assumed that osteoblasts in the human support osteoclast formation, in vitro evidence of this is currently lacking. We tested the ability of normal human trabecular bone-derived osteoblasts (NHBCs) to support osteoclast formation from human peripheral blood mononuclear cells (PBMC) in response to treatment with either 1alpha,25-dihydroxyvitamin D3 (1,25D) or parathyroid hormone (PTH), using a serum-replete medium previously used to support human osteoclast formation on a stroma of murine ST-2 cells. Under these conditions, NHBC did not support osteoclast formation, as assessed by morphological, histochemical, and functional criteria, despite our previous results demonstrating a link between induction of RANKL mRNA expression and NHBC phenotype in these media. We next tested a defined, serum-free medium (SDM) on NHBC phenotype, their expression of RANKL and OPG, and their ability to support osteoclast formation. SDM, containing dexamethasone (DEX) and 1,25D, induced phenotypic maturation of NHBC, based on the expression of STRO-1 and the bone/liver/kidney isoform of alkaline phosphatase (AP). PTH as a single factor did not induce phenotypic change. 1,25D and DEX induced the greatest ratio of RANKL:OPG mRNA, predictive of supporting osteoclast formation. Consistent with this, co-culture of NHBC with CD14+ PBMC, or bone marrow mononuclear cell (BMMC), or CD34+ BMMC precursors in SDM + 1,25D + DEX, resulted in functional osteoclast formation. Osteoclast formation also occurred in PTH + DEX stimulated co-cultures. Interestingly, SDM supplemented with recombinant RANKL (25-100 ng/ml) and M-CSF (25 ng/ml), did not induce osteoclast formation from any of the osteoclast precursor populations in stromal-free cultures, unlike serum-replete medium. This study demonstrates that under the appropriate conditions, adult human primary osteoblasts can support de novo osteoclast formation, and this model will enable the detailed study of the role of both cell types in this process. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15573398     DOI: 10.1002/jcp.20255

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  14 in total

1.  Construction of Sox9 gene eukaryotic expression vector and its inductive effects on directed differentiation of bone marrow stromal cells into precartilaginous stem cells in rats.

Authors:  Weihua Hu; Fengjing Guo; Feng Li; Hui Huang; Weikai Zhang; Anmin Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

2.  A simplified method for the generation of human osteoclasts in vitro.

Authors:  James J Cody; Angel A Rivera; Jianzhong Liu; Julian M Liu; Joanne T Douglas; Xu Feng
Journal:  Int J Biochem Mol Biol       Date:  2011-04-23

3.  Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate.

Authors:  Behnam Eslami; Shuanhu Zhou; Inge Van Eekeren; Meryl S LeBoff; Julie Glowacki
Journal:  Calcif Tissue Int       Date:  2011-02-15       Impact factor: 4.333

4.  Influence of receptor activator of nuclear factor (NF)-kappaB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fetal calf serum on human osteoclast formation and activity.

Authors:  Ludwika Kreja; Astrid Liedert; Carla Schmidt; Lutz Claes; Anita Ignatius
Journal:  J Mol Histol       Date:  2007-06-19       Impact factor: 2.611

5.  The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.

Authors:  S Kwan Tat; J-P Pelletier; D Lajeunesse; H Fahmi; M Lavigne; J Martel-Pelletier
Journal:  Clin Exp Rheumatol       Date:  2008 Mar-Apr       Impact factor: 4.473

6.  The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions.

Authors:  Cristina Vincent; Masakazu Kogawa; David M Findlay; Gerald J Atkins
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

7.  TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis.

Authors:  Anak A S S K Dharmapatni; Malcolm D Smith; Tania N Crotti; Christopher A Holding; Cristina Vincent; Helen M Weedon; Andrew C W Zannettino; Timothy S Zheng; David M Findlay; Gerald J Atkins; David R Haynes
Journal:  Arthritis Res Ther       Date:  2011-03-24       Impact factor: 5.156

8.  Effects of Osteogenic-Conditioned Medium from Human Periosteum-Derived Cells on Osteoclast Differentiation.

Authors:  Hyun-Chang Park; Young-Bum Son; Sung-Lim Lee; Gyu-Jin Rho; Young-Hoon Kang; Bong-Wook Park; Sung-Hoon Byun; Sun-Chul Hwang; In-Ae Cho; Yeong-Cheol Cho; Iel-Yong Sung; Dong Kyun Woo; June-Ho Byun
Journal:  Int J Med Sci       Date:  2017-11-02       Impact factor: 3.738

9.  Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study.

Authors:  Steeve Kwan Tat; Jean-Pierre Pelletier; Josep Vergés; Daniel Lajeunesse; Eulàlia Montell; Hassan Fahmi; Martin Lavigne; Johanne Martel-Pelletier
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

10.  Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling.

Authors:  Blair Hopwood; Anna Tsykin; David M Findlay; Nicola L Fazzalari
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.